[ad_1]

LONDON–(BUSINESS WIRE)–MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (RNAa) therapeutics, publicizes the enlargement of its Board, with the appointment of Susan Clement-Davies and Professor Sir Robert Lechler as Independent Directors, efficient 1 January 2022.

Susan is an skilled life sciences financier with over 25 years of capital markets and funding banking expertise, together with as Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and Managing Director at Torreya Partners LLC. Susan is presently a Non-Executive Director of Scancell Holdings, a UK listed biotechnology firm growing revolutionary immunotherapies, EvgenPharma plc, a UK-listed scientific stage drug improvement firm, and Exploristics, a world-leading supplier of biosimulation software program and biostatistics companies for scientific trials. Susan can be Corporate Finance Advisor for Theolytics, a biotechnology firm growing anticancer viral therapies, and an Advisor for Oxford Sciences Innovation, the world’s largest university-partnered enterprise agency. In addition, Susan is a member of the Innovation Advisory Group for the Chelsea and Westminster Hospital NHS Foundation Trust.

Robert is a recognised chief in biomedical analysis, administration and governance with over 40 years of distinguished expertise in tutorial medication, having began his immunology profession in 1979. Since then, Robert has held numerous management roles in a variety of hospitals and laboratories, together with serving as Head of Imperial College London’s Division of Medicine, Vice Principal (Health) of King’s College School, and Executive Director of King’s Health Partners Academic Health Sciences Centre. He has additionally been on the forefront of scientific innovation, nationally, by his Presidency of the Academy of Medical Sciences, Membership of the UK Council for Science and Technology, and Chairmanship of the UK MHRA Clinical Trials Expert Advisory Group. In 2012, Robert was Knighted within the Queen’s Birthday Honours for his companies to tutorial medication, which has centred round immunology, most cancers and transplantation. He is presently a Non-executive Director of Quell Therapeutics, a biopharmaceutical firm specialising in addressing a variety of autoimmune and inflammatory ailments by cell remedy.

Nagy Habib, Chairman and Head of R&D of MiNA Therapeutics, commented:

“We are thrilled to welcome Susan and Robert to MiNA’s Board of Directors to help our strengthened senior management crew as we stay centered on driving the Company’s subsequent section of progress. Susan’s experience in finance and as a biopharma firm director, mixed with Robert’s management in biomedicine can be invaluable as we proceed to advance our pipeline by scientific improvement and increase our partnerships to scale and amplify the impression of our pioneering RNAa know-how for sufferers.”

Susan Clement-Davies, Independent Director of MiNA Therapeutics, commented:

“I’m extraordinarily excited to be becoming a member of MiNA. What the crew has achieved, significantly lately, is spectacular and I hope to convey my expertise within the life sciences sector to additional unlock MiNA’s vital potential.”

Professor Sir Robert Lechler, Independent Director of MiNA Therapeutics, commented:

“This is a incredible alternative to be concerned with a pioneering firm in such an fascinating house. The Company’s RNAa strategy and pipeline is a really revolutionary manner of treating ailments and I look ahead to guiding MiNA on its journey, which I consider can be extremely profitable.”

About MiNA Therapeutics

MiNA Therapeutics is the chief in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that may restore or enhance regular operate in sufferers’ cells. We are advancing a proprietary pipeline of latest medicines with an preliminary concentrate on most cancers and genetic ailments, whereas collaborating with main pharmaceutical firms to use our know-how platform throughout a broad vary of therapeutic areas. Based on our distinctive know-how in RNA activation we’re increasing the probabilities of RNA-based medication for sufferers. www.minatx.com

[ad_2]

Source link

#MiNA #Therapeutics #Appoints #Independent #Directors #Extensive #Industry #Experience #Support #Phase #Growth

By Seth A. Dunbar

Seth A. Dunbar leads clinical research study operations and quality & compliance. His is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *